Duality Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Duality Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-65,143	Closed	-$3.34M	–	601
2023 Q4	$3.34M	Buy	65,143 +61,525	+1,701%	+$3.23M	0.35%	79
2023 Q3	$210K	Buy	+3,618	New	+$222K	0.03%	519
2023 Q1	–	Sell	-28,553	Closed	-$2.05M	–	569
2022 Q4	$2.05M	Buy	+28,553	New	+$2.15M	0.23%	150
2022 Q3	–	Sell	-59,411	Closed	-$4.58M	–	546
2022 Q2	$4.58M	Buy	+59,411	New	+$4.52M	0.45%	36
2022 Q1	–	Sell	-104,878	Closed	-$6.54M	–	644
2021 Q4	$6.54M	Buy	104,878 +20,062	+24%	+$1.18M	0.71%	15
2021 Q3	$5.02M	Buy	84,816 +60,313	+246%	+$3.97M	0.38%	78
2021 Q2	$1.64M	Buy	+24,503	New	+$1.6M	0.15%	239
2021 Q1	–	Sell	-7,138	Closed	-$443K	–	537
2020 Q4	$443K	Buy	+7,138	New	+$439K	0.03%	454
2019 Q4	–	Sell	-373,760	Closed	-$19M	–	381
2019 Q3	$19M	Buy	373,760 +230,530	+161%	+$10.8M	1.06%	11
2019 Q2	$6.5M	Buy	+143,230	New	+$6.67M	0.57%	43

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Duality Advisers's BMY Position: Q1 2024 in Review

Duality Advisers sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 65,143 shares — an estimated $3.34M sold.

Duality Advisers first reported a position in BMY in Q2 2019 and held it in 10 quarters. The position peaked at $19M in Q3 2019. 2,331 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

Duality Advisers reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
Duality Advisers sold 65,143 Bristol-Myers Squibb shares in Q1 2024, an estimated $3.34M.
Duality Advisers first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 10 quarters.
Duality Advisers's Bristol-Myers Squibb position peaked at $19M in Q3 2019.
2,331 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Duality Advisers's 13F filing for Q1 2024, filed 6 May 2024.